CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
侵袭性 B 细胞淋巴瘤的 CAR-T 细胞治疗
英文原题：Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma.
查看英文原题
Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种革命性疗法，越来越多地用于治疗非霍奇金B细胞淋巴瘤。本综述聚焦于CAR-T 细胞疗法在侵袭性B细胞淋巴瘤中的应用，包括临床适应证、已知的短期和长期毒性、CAR-T 细胞疗效与肿瘤耐药的机制，以及CAR-T 细胞疗法治疗侵袭性淋巴瘤的未来方向。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary therapy increasingly used in the treatment of non-Hodgkin B-cell lymphoma. This review focuses on the use of CAR T-cell therapy in aggressive B-cell lymphoma including clinical indications, known short- and long-term toxicity, mechanisms of CAR T-cell efficacy and tumor resistance, and future directions in the treatment of aggressive lymphoma with CAR T-cell therapy.
论文信息
- 作者
- Hamilton MP、Miklos DB
- 单位
- Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: mphamilt@stanford.edu.United States
- 文献类型
- 综述 · 美国 NIH 资助研究
- 期刊
- Hematology/oncology clinics of North America2023 Dec
- 原文标识
- PubMed 37349153 · DOI 10.1016/j.hoc.2023.05.007